Matthew T. Wiley's Insider Trades & SAST Disclosures

Matthew T. Wiley's most recent trade in Mind Medicine Inc was a trade of 350,000 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on March 17, 2025.

Stock Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
Mind Medicine Inc
Matthew T. Wiley Chief Commercial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Mar 2025 350,000 350,000 - - Stock Option (Right to Buy)
BioXcel Therapeutics Inc
Matthew T. Wiley Chief Commercial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 17 Sep 2024 21,250 25,283 (0%) 0% - Common Stock
BioXcel Therapeutics Inc
Matthew T. Wiley Chief Commercial Officer Sale of securities on an exchange or to another person at price $ 0.55 per share. 17 Sep 2024 6,272 19,011 (0%) 0% 0.6 3,450 Common Stock
BioXcel Therapeutics Inc
Matthew T. Wiley Chief Commercial Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 15 Sep 2024 750 4,248 (0%) 0% - Common Stock
BioXcel Therapeutics Inc
Matthew T. Wiley Chief Commercial Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 15 Sep 2024 750 7,500 - - Restricted Stock Units
BioXcel Therapeutics Inc
Matthew T. Wiley Chief Commercial Officer Sale of securities on an exchange or to another person at price $ 0.69 per share. 15 Sep 2024 215 4,033 (0%) 0% 0.7 149 Common Stock
BioXcel Therapeutics Inc
Matthew T. Wiley See Remarks Grant, award, or other acquisition of securities at price $ 0.00 per share. 22 Jul 2024 1,875 1,875 - - Stock Option (right to buy)
BioXcel Therapeutics Inc
Matthew T. Wiley Chief Commercial Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 15 Jun 2024 750 3,742 (0%) 0% - Common Stock
BioXcel Therapeutics Inc
Matthew T. Wiley Chief Commercial Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 15 Jun 2024 750 8,250 - - Restricted Stock Units
BioXcel Therapeutics Inc
Matthew T. Wiley Chief Commercial Officer Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 15 Jun 2024 750 8,250 - - Restricted Stock Units
BioXcel Therapeutics Inc
Matthew T. Wiley Chief Commercial Officer Sale of securities on an exchange or to another person at price $ 1.26 per share. 15 Jun 2024 244 3,498 (0%) 0% 1.3 308 Common Stock
BioXcel Therapeutics Inc
Matthew T. Wiley CHIEF COMMERCIAL OFFICER Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 15 Mar 2024 3,000 9,000 - - Restricted Stock Units
BioXcel Therapeutics Inc
Matthew T. Wiley CHIEF COMMERCIAL OFFICER Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 15 Mar 2024 3,000 3,000 (0%) 0% - Common Stock
BioXcel Therapeutics Inc
Matthew T. Wiley CHIEF COMMERCIAL OFFICER Sale of securities on an exchange or to another person at price $ 2.63 per share. 15 Mar 2024 1,008 2,992 (0%) 0% 2.6 2,656 Common Stock
BioXcel Therapeutics Inc
Matthew T. Wiley CHIEF COMMERCIAL OFFICER Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Mar 2023 36,000 36,000 - - Stock Option (Right to Buy)
BioXcel Therapeutics Inc
Matthew T. Wiley CHIEF COMMERCIAL OFFICER Grant, award, or other acquisition of securities at price $ 0.00 per share. 15 Mar 2023 12,000 12,000 - - Restricted Stock Units
VYNE Therapeutics Inc
Matthew T. Wiley Chief Commercial Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.51 per share. 30 Jun 2021 5,151 109,246 (0%) 0% 3.5 18,080 Common Stock
VYNE Therapeutics Inc
Matthew T. Wiley Chief Commercial Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.84 per share. 31 Mar 2021 2,573 114,397 (0%) 0% 6.8 17,599 Common Stock
VYNE Therapeutics Inc
Matthew T. Wiley Chief Commercial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 22 Feb 2021 64,575 64,575 - - Stock Options
VYNE Therapeutics Inc
Matthew T. Wiley Chief Commercial Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 22 Feb 2021 27,675 116,970 (0%) 0% 0 Common Stock
VYNE Therapeutics Inc
Matthew T. Wiley Chief Commercial Officer Grant, award, or other acquisition of securities at price $ 1.45 per share. 30 Nov 2020 7,838 358,722 (1%) 0% 1.4 11,326 Common Stock
VYNE Therapeutics Inc
Matthew T. Wiley Chief Commercial Officer Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.66 per share. 30 Sep 2020 1,541 350,884 (1%) 0% 1.7 2,558 Common Stock
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades